Insmed

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $1.14 billion, up 185% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$0.81 billion.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.03 billion, up 50% from a year earlier.SEC EDGAR filings (XBRL)
• Latest earnings call or results release (August 6, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
• Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed February 19, 2026): 4 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $42.9 million on the open market.SEC Form 4
• 666 institutional managers reported a position at June 30, 2026 (−8 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 4 (10 a year earlier).U.S. Department of Labor (OFLC)

Risk events (12 months): 1 — latest OSHA inspection, Jan 15, 2026 →

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Insmed yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name Insmed, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

2 headlines

0% positive · 0% negative

90 days

2 headlines

0% positive · 0% negative

• Neutral
  Insmed CFO Sara Bonstein to Resign; INSM Reaffirms 2026 Revenue Guidance

  gurufocus.com · via Marketaux · Oct 5, 2026

• Neutral
  Insmed CFO Sara Bonstein to step down, reaffirms guidance (INSM:NASDAQ)

  seekingalpha.com · via Marketaux · Oct 5, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 20268-K
   Director or officer changeItem 5.02
2. Oct 19, 2026Lobbying
   Lobbying report (LMH STRATEGIC SOLUTIONS)third_quarter 2026 · $0.1 million
3. Oct 5, 20268-K
   Director or officer changeItem 5.02
4. Jul 20, 2026Lobbying
   Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)second_quarter 2026 · $0.0 million
5. Jul 19, 2026Lobbying
   Lobbying report (LMH STRATEGIC SOLUTIONS)second_quarter 2026 · $0.0 million
6. Jul 17, 2026Lobbying
   Lobbying report (LMH STRATEGIC SOLUTIONS)second_quarter 2026
7. Jul 14, 2026Patent
   Patent granted: LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOFUS 12679815
8. May 15, 20268-K
   Shareholder vote resultsItem 5.07
9. May 5, 2026Patent
   Patent granted: METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSUS 12616708
10. Apr 20, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)first_quarter 2026 · $0.0 million
11. Feb 19, 20268-K
    Director or officer changeItem 5.02
12. Feb 19, 202610-K
    Annual report (10-K)4 risk factors added, 1 removed
13. Jan 20, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)fourth_quarter 2025 · $0.0 million
14. Jan 15, 2026Risk event
    OSHA complaint inspection: INSMEDOSHA
15. Jan 13, 2026Patent
    Patent granted: LARGE-SCALE MANUFACTURING METHODS FOR AMINOGLYCOSIDESUS 12521345
16. Nov 25, 2025Patent
    Patent granted: REVERSIBLE DPP1 INHIBITORS AND USES THEREOFUS 12479837
17. Oct 20, 2025Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)third_quarter 2025 · $0.0 million
18. Aug 5, 2025Patent
    Patent granted: METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSUS 12377114
19. Jul 14, 2025Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)second_quarter 2025 · $0.0 million
20. May 16, 20258-K
    Director or officer changeItem 5.02
21. May 16, 20258-K
    Shareholder vote resultsItem 5.07
22. Apr 17, 20258-K
    Director or officer changeItem 5.02
23. Feb 20, 20258-K
    Director or officer changeItem 5.02
24. Feb 20, 202510-K
    Annual report (10-K)0 risk factors added, 2 removed
25. Nov 19, 20248-K
    Material agreement terminatedItem 1.02
26. Oct 31, 20248-K
    Material agreement signedItem 1.01
27. Feb 22, 202410-K
    Annual report (10-K)5 risk factors added, 0 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1104506